☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Astellas
Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer
March 29, 2024
Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan
March 4, 2024
Astellas Reports the Submission of sNDA to the Japan MHLW for Padcev in Combination with Keytruda to Treat Advanced Bladder Cancer
January 31, 2024
Astellas Receives the EMA’s Validation on Type II Variation Application for Padcev (enfortumab vedotin) in Combination with Keytru...
January 29, 2024
Astellas Enters into a Research Collaboration and License Agreement with Elpiscience to Develop Bispecific Macrophage Engagers to...
December 28, 2023
Astellas & Seagen Reports the US FDA’s Acceptance of sBLA with Priority Review for Padcev (enfortumab vedotin-ejfv) + Keytruda to...
December 1, 2023
Load more...
Back to Home